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Background: The present study provides a contemporary and comprehensive summation of midterm patency rates of
polyester (Dacron) or polytetrafluoroethylene (PTFE) grafts in femoropopliteal bypass grafting based on a meta-analysis
consisting only of randomized controlled trials.
Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched to identify all
randomized controlled trials of Dacron vs PTFE grafts in femoropopliteal bypass grafting. Seven trials were found.
Survival data were combined to yield the pooled cumulative primary patency. We estimated the log hazard ratio (HR) for
each 1-month interval and then combined the HRs in a stratified way across intervals to obtain an overall log HR for each
trial. Study-specific estimates were combined using inverse variance-weighted averages of logarithmicHRs in fixed-effects
and random-effects models.
Results: The pooled cumulative primary patency of Dacron and PTFE grafts was, respectively, 60.2% (95% confidence interval
[CI], 56.4%-64.0%) and 53.8% (95% CI, 46.8%-60.9%) at 3 years, and 49.2% (95% CI, 45.6%-52.7%) and 38.4% (95% CI,
32.2%-44.6%) at 5 years. Pooled analysis of the seven trials demonstrated no difference inHR for graft occlusion with Dacron
relative to PTFE grafts (random-effects HR, 0.87; 95% CI, 0.67-1.12; P  .27 for effect; P  .03 for heterogeneity).
Conclusion: Either Dacron or PTFE grafts can be used in femoropopliteal bypass grafting with no significant differences
in midterm graft patency at 5 years (49.2% vs 38.4%) when the autologous saphenous vein is unavailable. ( J Vasc Surg
2010;52:232-6.)Different materials can be used for femoropopliteal
bypass grafting, including autologous and homologous
grafts from the saphenous vein or the human umbilical vein
as well as prosthetic graft materials such as polytetrafluoro-
ethylene (PTFE) or polyester (Dacron) grafts.1 Meta-
analyses2,3 of randomized controlled trials (RCTs) have
demonstrated that saphenous vein graft patency is superior
to PTFE graft patency in above-knee femoropopliteal by-
pass grafting.
A recent meta-analysis of RCTs of Dacron vs PTFE
grafts as bypass materials for peripheral vascular surgery
showed no evidence of a patency advantage of one synthetic
material compared with the other.1 The study, however,
included not only femoropopliteal but also femorofemo-
ral,4,5 axillofemoral,5 and aortoiliac6 bypass grafting. It also
did not meta-analyze RCTs of femoropopliteal bypass
grafting exclusively. Furthermore, a most recent RCT,7 not
included in the previous meta-analysis,1 showed that Da-
cron femoropopliteal bypass graft patency was superior to
PTFE graft patency.
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232The objective of the present study was to provide a
contemporary meta-analysis of patency rates of Dacron and
PTFE using only RCTs of extremity bypass below the
inguinal ligament. An additional objective was to establish
a comprehensive but concise midterm patency benchmark
for vascular providers.
METHODS
Search strategy. All RCTs of Dacron vs PTFE grafts
in femoropopliteal bypass grafting were identified using a
two-level search strategy. First, public domain databases,
including MEDLINE, EMBASE, and the Cochrane Cen-
tral Register of Controlled Trials, were searched using the
PubMed and OVID Web-based search engines. Second,
relevant studies were identified through a manual search of
secondary sources, including references of initially identi-
fied articles and a search of reviews and commentaries. All
references were downloaded for consolidation, elimination
of duplicates, and further analysis.
The MEDLINE (from January 1966), EMBASE data-
bases (from January 1991), and the Cochrane Library and
Central Register of Controlled Trials were searched
through October 2009. MeSH keywords included polyeth-
ylene terephthalate, polytetrafluoroethylene, and randomized
controlled trial. Exploding keywords included femoropopli-
teal, polyethylene terephthalate, Dacron, polytetrafluoroethyl-
ene, PTFE, and randomized controlled trial.
Study selection and data abstraction. Studies con-
sidered for inclusion met the following criteria: the design
was an RCT, the study population comprised patients
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were randomly assigned to femoropopliteal bypass grafting
with Dacron vs PTFE grafts. Data regarding detailed inclu-
sion criteria, graft type, duration of follow-up, primary
patency, and hazard ratio (HR) for graft occlusion were
abstracted (as available) from each individual study. The
survival (patency) data were extracted from the text, life
tables, and survival curves that showed the number of grafts
at risk for at least some intervals.
Statistical analysis. The pooled cumulative primary
patency was yielded by means of a strategy to combine
survival data constructed by Pereira et al.8 In the first step,
we redistributed in equal quantities at 1-month intervals
grafts censored at intervals 1 month. Next, we obtained
the numbers of failed grafts for intervals of 1 month by
using the grafts at risk at the start of an interval, the
redistributed censored units, and the interval hazard rates.
We then calculated the Kaplan-Meier success rates for each
series and each month of follow-up and used these rates as
treatment effects.
In the second step, we calculated a within-series vari-
ance for each monthly success rate in each series; next, we
calculated a between-series variance for each month. To
obtain pooled measures of treatment effect for each month
of follow-up, we used in the third step random-effects
modeling. Finally, the product of successive monthly
pooled measures of treatment effect allowed us to obtain
pooled measures of cumulative success and to calculate
approximate standard errors.
Using the method of Parmar et al,9 we estimated the
logHR for each 1-month interval and then combined them
in a stratified way across intervals to obtain an overall log
HR for each trial. We exploited the fact that when time to
an event and censoring are not formally included in the
calculation, the HR is estimated by the relative risk. Diffi-
culties with calculating the log HR and its variance arose
whenever the effective number of graft occlusions in the
Dacron or PTFE arm was zero; that is, there was no graft
occlusion in that interval in the Dacron or PTFE arms. To
calculate the log HR and its variance in such circumstances,
the zero was replaced by a small number of graft occlusions,
say 10–6, in that interval.
The overall log HR for each trial was given by a
weighted sum of the individual estimates of the log HR
during each time interval, where the weights are inversely
proportional to the variance of each estimate. Estimated
ratios and their variances were used to construct 95% con-
fidence intervals (CIs) for parameters of interest for indi-
vidual studies and for the summary measure.
Study-specific estimates were combined using inverse
variance-weighted averages of logarithmic HRs in both
fixed-effects and random-effects models. Where no signifi-
cant statistical heterogeneity was identified, the fixed-effect
estimate was used preferentially as the summary measure.
Between-study heterogeneity was analyzed by means of
standard 2 tests. Sensitivity analyses were performed to
assess the contribution of each study to the pooled estimate
by excluding individual trials one at a time and recalculatingthe pooled HR estimates for the remaining studies. Publi-
cation bias was assessed graphically using a funnel plot and
mathematically using a linear regression test, according to
the method of Egger et al.10 All analyses were conducted
using Excel 11.5.0 software (Microsoft Corp, Redmond,
Wash), ReviewManager (RevMan) 5.0 softare,11 and MIX
1.61 software.12
RESULTS
Our search identified seven RCTs7,13-18 of Dacron vs
PTFE grafts in femoropopliteal bypass grafting. Our
meta-analysis included data on 1521 patients, of whom
755 were randomized to femoropopliteal bypass grafting
with Dacron and 766 with PTFE. Dacron graft types
included collagen-impregnated,7,17 gelatin-sealed (gelatin-
coated),13,18collagen-coatedheparin-bonded,14fluoropolymer-
coated,15 and unsealed.16 Expanded PTFE grafts were
used in two trials.7,17 Three7,13,17 of the seven RCTs
consisted of patients undergoing above knee femoro-
popliteal bypass grafting only, whereas four trials in-
cluded below knee grafting in 14%,14 27%,16 31%,18 and
41%15 of patients, respectively. Duration of follow-up
was 2 years,13 3 years,15 4 years,16,18 5 years,14,17 and 10
years.7 Although only van Det et al7 reported 10-year
results, we abstracted the 5-year outcomes because the
other six RCTs provided 5-year results.
The pooled cumulative primary patency of Dacron and
PTFE grafts was respectively 74.7% (95%CI, 68.5%-80.8%)
and 73.9% (95% CI, 65.4%-82.4%) at 1 year; 65.9% (95%
CI, 62.2%-69.7%) and 60.7% (95% CI, 55.1%-66.3%) at 2
years; 60.2% (95% CI, 56.4%-64.0%) and 53.8% (95% CI,
46.8%-60.9%) at 3 years; 54.9% (95% CI, 51.0%-58.8%)
and 45.9% (95% CI, 40.4%-51.4%) at 4 years; and 49.2%
(95% CI, 45.6%-52.7%) and 38.4% (95% CI, 32.2%-44.6%)
at 5 years (Fig 1).
Two7,13 of the seven RCTs demonstrated a statistically
significant benefit of Dacron over PTFE grafts for patency
in patients undergoing femoropopliteal bypass grafting.
Only the trial by Robinson et al (2003),15 which used
fluoropolymer-coated Dacron grafts, demonstrated a sta-
tistically significant reduction in patency with Dacron com-
Fig 1. Pooled primary patency. PTFE, polytetrafluoroethylene.pared with PTFE grafts. Pooled analysis of the seven trials
; SE,
, Con
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with Dacron relative to PTFE grafts (random-effects HR,
0.87; 95% CI, 0.67-1.12; P  .27 for effect; P  .03 for
heterogeneity; Fig 2).
We performed several sensitivity analyses to assess the
effect of qualitative heterogeneity in trial design and patient
selection on the pooled effect estimate. Exclusion of any
single trial from analysis, except for the trial by Robinson et
al,15 did not substantively alter the overall result of our
analysis. Eliminating the Robinson et al trial substantially
changed the pooled point estimate (fixed effects HR, 0.75;
95% CI, 0.63-0.89; P  .0009 for effect; P  .89 for
heterogeneity; Fig 3).
When data from the three trials7,13,17 consisting exclu-
sively of above-knee femoropopliteal bypass grafting were
pooled (representing 884 patients), Dacron grafts were
associated with a statistically significant reduction in hazard
for graft occlusion relative to PTFE grafts (fixed effects HR,
0.71; 95% CI, 0.57-0.89; P  .003 for effect; P  .76 for
heterogeneity; Fig 4). To assess publication bias, we gen-
Fig 2. Forest plot shows the hazard ratio for graft occlu
seven trials. CI, Confidence interval; IV, inverse variance
Fig 3. Forest plot shows the hazard ratio for graft occlu
trials, except for the trial by Robinson et al (2003).15 CI
Fig 4. Forest plot shows the hazard ratio for graft occl
three trials consisting exclusively of above-knee femorop
variance; SE, standard error.erated a funnel plot of the effect size vs the standard errorfor each trial (Fig 5) and found no evidence of significant
publication bias (P  .102 by Egger regression test).
DISCUSSION
The results of our analysis suggest that there may be no
difference in patency between Dacron and PTFE grafts in
femoropopliteal bypass grafting at 5 years (49.2% vs
38.4%). Our analysis must be viewed in the context of its
limitations:
First, the Dacron arms included collagen-impregnated,
gelatin-sealed (gelatin-coated); collagen-coated, heparin-
bonded; fluoropolymer-coated; and unsealed grafts. Ex-
cluding the trial that used fluoropolymer-coated Dacron
grafts demonstrated a statistically significant reduction in
the hazard for graft occlusion with Dacron relative to PTFE
grafts.
Second, three of the seven trials included in our analysis
consisted of patients undergoing above-knee femoropopli-
teal bypass grafting only, whereas four trials included below-
knee grafting. Combining the three trials consisting of above-
f Dacron vs polytetrafluoroethylene (PTFE) grafts in all
standard error.
f Dacron vs polytetrafluoroethylene (PTFE) grafts in six
fidence interval; IV, inverse variance; SE, standard error.
of Dacron vs polytetrafluoroethylene (PTFE) grafts in
eal bypass grafting. CI, Confidence interval; IV, inversesion osion ousion
oplitknee femoropopliteal bypass grafting exclusively showed a
ffect
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occlusion.
Despite these limitations, however, our study has merit
as a contemporary, comprehensive summation of 2- to
5-year patency rates using the best studies available (ie,
RCTs and infrainguinal only).
Although the saphenous vein is considered to be the
gold standard for below-knee femoropopliteal bypass graft-
ing, there had been controversy about whether prosthetic
materials (PTFE, Dacron, and the human umbilical vein)
are equivalent to the autologous saphenous vein for above-
knee femoropopliteal bypass grafting.3 Prosthetic bypass
material, however, may be needed if the saphenous vein is
absent or not suitable for bypass grafting.
Klinkert et al3 performed systematic review of studies
comparing the patency of saphenous vein and PTFE as
bypass material for above-knee femoropopliteal bypass.
When only RCTs were considered, venous bypasses were
superior to PTFE bypasses at all intervals studied. The
primary patency rate of venous and PTFE bypasses was 80%
and 69%, respectively, after 2 years and was 74% and 39%,
respectively, after 5 years.
Those authors, however, could not perform a statistical
comparison of the patency rates for vein and PTFE; there-
fore, we2 performed an updated meta-analysis of RCTs.
The pooled primary graft patency of saphenous vein and
PTFE were 82.6% and 74.6% at 2 years (risk ratio for
occlusion in PTFE vs saphenous vein, 1.34; 95% CI, 1.05-
1.70; P .0198) and 76.4% and 56.1% at 5 years (risk ratio,
1.68; 95% CI, 1.34-2.11; P  .0001), respectively. These
results of the meta-analyses suggest that saphenous vein
graft patency is superior to PTFE graft patency in above-
knee femoropopliteal bypass grafting.
Meanwhile, PTFE with a vein cuff interposed at the
distal anastomosis is a reasonable substitute when vein is
Fig 5. Funnel plot shows the enot available.19,20 Heparin-bonded expanded PTFE graftsalso provide good long-term results in infragenicular by-
passes21 and had primary patency results that were not
significantly different from those for saphenous vein
grafts.22 Furthermore, the patency rates of PTFE grafts to
infrageniculate vessels may be improved by effective anti-
coagulation with warfarin, and this improved patency rate
may also result in improved limb salvage and further sup-
ports the use of PTFE grafts for critical limb ischemia when
autogenous vein is not available.23
The next issue is which Dacron or PTFE grafts should
be used when the autologous saphenous vein is unavailable.
Roll et al1 performed a systematic review and meta-analysis
of RCTs to compare the effectiveness of Dacron and PTFE
grafts in peripheral vascular bypass surgery. Meta-analysis
on the comparison of PTFE vs Dacron grafts yielded no
differences with regard to primary patency rates (HR for
occlusion in PTFE vs Dacron, 1.04; 95% CI, 0.85-1.28;
P  .72). The meta-analysis, however, included not only
femoropopliteal but also femorofemoral,4.5 axillofemoral,5
and aortoiliac6 bypass grafting.
The results of RCTs of Dacron vs PTFE grafts for
femoropopliteal bypass grafting are controversial. The re-
sults of our meta-analysis of RCTs of Dacron vs PTFE
grafts exclusively in femoropopliteal bypass grafting sug-
gest that Dacron and PTFE grafts have similar midterm (2-
to 5-year) primary patency. However, the RCT by van Det
et al7 showed that Dacron femoropopliteal bypass grafts
had superior patency compared with PTFE grafts during
prolonged 10-year follow-up. Long-term (5-year) fol-
low-up results may be needed to assess which graft should
be used in femoropopliteal bypass grafting.
Only the trial by Robinson et al15 demonstrated a
statistically significant occlusion increase with Dacron over
PTFE grafts, and our sensitivity analysis eliminating that
particular trial resulted in a statistically significant reduction
size vs the standard error (SE).in hazard for graft occlusion with Dacron relative to PTFE
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Dacron graft in the Robinson et al15 trial was due to graft
thrombosis mostly in the first month. The reason for the
early thrombosis in the fluoropolymer-coated Dacron graft
is unknown; however, it occurred more frequently in pa-
tients with previously documented poor prognostic indica-
tors of graft survival, namely, critical limb ischemia, below-
knee distal anastomosis, and grafts with a smaller diameter
(6 mm). A possible explanation is that differences between
graft types are more likely to be detected in patients with
poor prognostic indicators and a higher rate of occlusion
because the statistical power of a study for a given number
of patients is greater if the occlusion rate is higher.15
CONCLUSIONS
Either Dacron or PTFE grafts can be used in femoro-
popliteal bypass grafting with no significant differences in
midterm graft patency (49.2% vs 38.4% at 5 years) when the
autologous saphenous vein is unavailable. Dacron grafts,
however, when not fluoropolymer-coated or used in above-
knee bypass grafting, may be superior to PTFE grafts for
patency.
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